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Abstract
Background: Complex interactions involving genetic susceptibility and environmental factors are thought to
underlie the pathogenesis of Parkinson’s disease (PD). Although the role of inflammatory processes in modulating
risk for development of PD has yet to be fully understood, prospective studies suggest that chronic use of NSAIDs
reduce the incidence of PD. Loss-of-function mutations in the DJ-1 gene cause a rare form of familial PD with an
autosomal recessive pattern of inheritance; however, DJ-1−/− mice do not display nigrostriatal pathway
degeneration, suggesting that additional factors such as inflammation may be needed to induce
neurodegeneration on the background of DJ-1 gene mutations. Neuroinflammation causes oxidative stress and,
based on evidence that DJ-1 plays a protective role against oxidative stress, we investigated whether DJ-1−/− mice
display increased vulnerability to inflammation-induced nigral degeneration.
Methods: We exposed adult wild-type and DJ-1−/− mice to repeated intranasal administration of soluble TNF
(inTNF) or repeated intraperitoneal injections of low-dose lipopolysaccharide (LPS) or saline vehicle. We measured
locomotor performance using a variety of behavior tasks, striatal dopamine (DA) content by HPLC, DA neuron (TH+ cells)
and total neuron (NeuN+ cells) number in the substantia nigra pars compacta and ventral tegmental area by unbiased
stereology, number of Iba1-positive microglia, and mRNA levels of inflammatory and oxidative stress genes by
quantitative PCR in the midbrain, cortex and isolated peritoneal macrophages of DJ-1−/− and wild-type mice.
Results: We found that chronic LPS injections induced similar neuroinflammatory responses in the midbrains of DJ-1−/−
mice and wild-type mice and neither group developed locomotor deficits or nigral degeneration. inTNF administration
did not appear to induce neuroinflammatory responses in LPS-treated wild-type or DJ-1−/− mice. The lack of
vulnerability to inflammation-induced nigral degeneration was not due to enhanced anti-oxidant gene responses in the
midbrains of DJ-1−/− mice which, in fact, displayed a blunted response relative to that of wild-type mice. Peripheral
macrophages from wild-type and DJ-1−/− mice displayed similar basal and LPS-induced inflammatory and oxidative
stress markers in vitro.
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Conclusions: Our studies indicate that DJ-1−/− mice do not display increased vulnerability to inflammation-related
nigral degeneration in contrast to what has been reported for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine. We
conclude that either DJ-1 does not have a critical role in protecting DA neurons against inflammation-induced oxidative
stress and/or there is compensatory gene expression in the midbrain of DJ-1−/− mice that renders them resistant to the
cytotoxic effects triggered by chronic peripheral inflammation.
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Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder. It is an age-dependent
disease characterized by a severe depletion of dopamine
(DA)-producing neurons in the substantia nigra pars
compacta (SNpc) that project to the striatum. The grad-
ual loss of nigrostriatal pathway function results in
slowly progressing clinical symptoms including tremor,
rigidity and slowness of movement. Despite intensive re-
search, the causes of PD remain unknown. Over the last
decade, a vast number of published studies have indi-
cated that inflammation-derived oxidative stress and
cytokine-dependent neurotoxicity are likely to contrib-
ute to nigrostriatal pathway degeneration [1-5], the
pathological hallmark of PD. Specifically, post-mortem
analyses of brains from PD patients confirmed the pres-
ence of inflammatory mediators in the area of the SNpc
where maximal destruction of melanin-containing DA-
producing neurons occurs [6-11]. Signs of inflammation
included activated microglia and accumulation of cyto-
kines (including TNF, IL-1β, IL-6, and IFNγ), some of
which exert neurotoxic effects on DA neurons [5]. In
addition to extrinsic factors, SNpc dopaminergic neu-
rons may be uniquely vulnerable to neuroinflammatory
insults that enhance cellular oxidative stress. For ex-
ample, the higher sensitivity of nigral DA neurons to in-
jury induced by neuroinflammatory mediators may be
secondary to a reduction of endogenous anti-oxidant
capacity (such as glutathione depletion). Pharmacologic-
ally, chronic infusion of various anti-inflammatory com-
pounds (including COX-2-selective NSAIDs or soluble
TNF-selective inhibitors) rescues nigral DA neurons
from progressive degeneration and death [12-14]. These
findings raise the interesting possibility that environmental
triggers may initiate cytokine-driven neuroinflammation
and may contribute to the development of PD in humans.
Monogenic forms of PD have been linked to loss-
of-function mutations in a number of genes, giving rise
to autosomal recessive parkinsonism [15], including muta-
tions in parkin, which encodes an E3 ligase, and in DJ-1,
which encodes a putative redox sensor that associates with
chaperones [16] and translocates to mitochondria during
conditions of oxidative stress [17-22]. In addition to its
proposed role as a redox sensor [23], DJ-1 may also have
important functions as an RNA binding protein [24].
Although DJ-1−/− mice have been reported to be hyper-
sensitive to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyrindine (MPTP) [25], and to display abnor-
malities in dopaminergic function when exposed to the
herbicide paraquat [26], these mice do not develop
nigrostriatal degeneration in the absence of stresses
[17,25,27-29]. Moreover, DJ-1−/− dopaminergic neu-
rons or siRNA-mediated knockdown of DJ-1 mRNA in
primary embryonic midbrain DA neurons resulted in in-
creased sensitivity to toxins that induce oxidative stress
[30]. DJ-1 is also abundantly expressed in non-neuronal
cells and the bacterial endotoxin lipopolysaccharide
(LPS) induces a robust increase in DJ-1 expression in in-
flammatory cells such as peritoneal macrophages [31].
LPS exposure causes astrocytes derived from DJ-1−/−
mice to generate ten times more nitric oxide than astro-
cytes derived from wild-type mice [32]. These studies
suggest that DJ-1 loss-of-function mutations affect both
neuronal and non-neuronal cell types and could result in
enhanced microglial activation upon neuroinflammatory
insults. Therefore, the purpose of our study was to investi-
gate whether loss of DJ-1 protein increases the vulnerabil-
ity for inflammation-induced nigrostriatal degeneration
in vivo. To this end, we investigated the extent to which
repeated intranasal administration of soluble tumor necro-
sis factor (inTNF) or repeated intraperitoneal (i.p) injec-
tions of low-dose LPS might induce neuroinflammation,
locomotor deficits, enhance oxidative stress and/or elicit




DJ-1−/− mice were generated and characterized as
described previously [17]. Prior to these studies, DJ-1
−/− mice were back-crossed onto a C57BL/6 genetic
background for over ten generations. Mice were housed
in a pathogen-free, climate controlled facility in the Ani-
mal Resources Center at The University of Texas South-
western Medical Center at Dallas and given food and
water ad libitum. All animal studies were reviewed and ap-
proved by the Institutional Animal Care and Use Commit-
tee at The University of Texas Southwestern Medical
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Center in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Intranasal tumor necrosis factor administration
Murine soluble TNF (0.5 ng or 5 ng delivered as 5 μL of
0.1 ng/uL or 5 μL of 1 ng/uL) or an equivalent amount
of saline vehicle was administered intranasally via an L-10
Pipetman (Rainin Instrument, Oakland, CA, USA) twice
weekly for the time indicated in each set of experiments.
Wild-type or DJ-1−/− mice were 12 months old at the
start of the study (Additional file 1: Figure S1A) and 15
months old at the time of sacrifice.
Systemic lipopolysaccharide administration
The regimen of LPS injections was chosen based on our
previous work which demonstrated that this dose and
frequency of i.p. LPS triggers a neuroinflammatory re-
sponse in the midbrain and elicits nigral DA neuron loss
in parkin−/− mice [33]. Young adult (6 to 13 week old)
DJ-1−/− mice on a C57BL/6 background and age-matched
wild-type mice were given either 7.5 × 105 EU/kg LPS from
Escherichia coli O111:B4 (Sigma-Aldrich, Saint Louis,
MO, USA) or sterile 0.9% sodium chloride vehicle con-
trol (Braun Medical, Inc., Irvine, CA, USA) i.p. injections
twice a week for 3 months. A second group of mice (des-
ignated as 3-month/3-month wait) was given systemic
LPS or vehicle i.p. injections for 3 months followed by a
3-month wait period prior to tissue collection, during
which no additional i.p. injections were administered
(n = 3 to 6 per group). A third group of mice was
given twice weekly systemic LPS or vehicle injections
for 6 months with no wait period before tissue collec-
tion (n = 3 to 7 per group). We would like to note that
the DJ-1−/− versus wild-type mouse studies reported in
this manuscript were performed alongside a cohort of
parkin−/− mice, the results of which were reported pre-
viously [33] in comparison to the same cohort of wild-
type mice used here.
Behavior testing
For all behavioral tests, mice were evaluated at baseline
(before i.p. injections began) and again after 3 or 6 months
of treatment.
Open-field
Open-field behavior in a glass container (diameter,
24.5 cm) was recorded for 5 minutes for evaluation of
time spent moving and number of rearing events by an in-
vestigator blinded to genotype and treatment history.
Narrow beam walk
A narrow beam (1.1 cm diameter, 80.6 cm testing length)
with a home cage at one end was used. Initial training
prior to treatment consisted of three sessions of three
trials per session for 4 consecutive days. Mice received
additional training sessions at 3 months and 6 months
after the start of the treatment regimen consisting of
three sessions of three trials per session on 1 day. Test-
ing was conducted the day after training and consisted
of one session of three trials. The average time to
traverse the full length of the beam was used for data
analysis.
Accelerating rotarod
A base speed of 20 rpm with an acceleration of 0.2 rpm/
second was used on the rotarod (Economex 0207–005 M,
Columbus Instruments, Columbus, OH, USA). Mice were
trained prior to treatment in three sessions of four trials
each for 4 consecutive days. Mice received additional
training sessions at 3 months and 6 months after the start
of treatment consisting of three sessions of four trials per
session on 1 day. Testing consisted of one session of three
trials the day after training was completed. Latency to fall
(seconds) was calculated and used for data analysis.
Tissue harvest
Following the last inTNF administration or i.p. injec-
tion and final behavioral testing, mice in the 3-month,
3-month/3-month wait, and 6-month treatment cohorts
were deeply anesthetized with Euthasol (pentobarbital
sodium and phenytoin sodium) i.p. then intracardially
perfused with warm 0.1 M PBS pH 7.4 supplemented
with 0.1% glucose and 1 U/mL heparin prior to rapid
whole brain removal. For quantitative real-time PCR
(QPCR), brain tissue was microdissected into four re-
gions on an ice-cold glass Petri dish - olfactory bulb,
cerebellum, ventral midbrain and cortex - then snap-
frozen in cryovials in liquid nitrogen and stored at −80°C
until processed for RNA extraction. For immunohisto-
chemistry, mice in the 3-month, 3-month/3-month wait,
and 6-month treatment cohorts were perfused with warm
0.1M PBS (pH 7.4 supplemented with 0.1% glucose and
1 U/mL heparin) followed by ice cold 4% paraformalde-
hyde in PBS (pH 7.4). Brains (in the skull) were post-
fixed overnight in 4% paraformaldehyde. Brains were
removed from the skull and then were cryoprotected
for 24 hours in 20% sucrose in 0.1 M PBS pH 7.4, embed-
ded in Neg 50 frozen section medium (Richard Allen
Scientific, Kalamazoo, MI, USA), and frozen in dry ice-
cooled isopentane.
Peritoneal macrophage harvest
Murine peritoneal macrophages were obtained by eliciting
an acute peripheral inflammatory reaction with an i.p.
injection of thioglycolate [34]. Briefly, adult mice were
given an i.p. injection of 3% Brewer’s yeast thioglycolate
in normal saline. Three days later, animals were euthanized
and peritoneal exudates were recovered, pelleted and
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resuspended in culture media (high-glucose DMEM supple-
mented with 10% heat-inactivated FBS from Atlanta Biologi-
cals (Norcross, GA, USA), 1% penicillin/streptomycin, and
1% L-glutamine (Sigma-Aldrich)). Six hours after the initial
plating, cells were washed twice with PBS without Ca2+ or
Mg2+ to remove non-adherent cells and growth medium
was replenished to the homogeneous population of adher-
ent macrophages.
Quantitative real-time polymerase chain reaction
Total RNA was isolated from tissue samples using Tri
Reagent® (Molecular Research Center, Cincinnati, OH,
USA), treated with DNAse I (Invitrogen, Carlsbad, CA,
USA), and reverse transcribed to obtain cDNA. QPCR
was performed using SYBR Green Master Mix (ABI) on
an Applied Biosystems Prism 7900HT sequence detection
system (Foster City, CA, USA) as described previously
[35]. Primers for each gene (available upon request) were
designed using Primer Express Software (PerkinElmer
Life Sciences, Wellesley, MA, USA) and were validated
by analysis of template titration and dissociation curves.
Results for QPCR were normalized to the housekeeping
gene cyclophilin B and evaluated by comparative CT
method (user bulletin No. 2, PerkinElmer Life Sciences).
RNA levels are expressed relative to the wild-type saline-
injected (vehicle) mice.
Immunohistochemistry
Coronal serial sections (30 μm thickness) were cut on a
Leica CM 1850 cryostat (Buffalo Grove, IL, USA) and
placed on Superfrost/Plus microscope slides (Fisher
Scientific; Pittsburgh, PA, USA). Sections on slides were
stored at −80°C until processed for immunohistochemistry.
Brightfield immunohistochemistry. Sections were stained
for tyrosine hydroxylase (TH) using published protocols
[36,37]. Sections were permeabilized in 0.3% Triton X-100
in PBS pH 7.4. Endogenous peroxidases were quenched
with 1% H2O2 and non-specific binding was blocked
with 5% normal serum (goat or horse, Equitech-Bio,
Inc., Kerrville, TX, USA). Sections were incubated with
primary antibodies against TH (rabbit polyclonal anti-
body AB152 diluted 1:2000, Chemicon International,
Temecula, CA, USA), or neuronal nuclear antigen (NeuN)
(mouse monoclonal antibody MAB377 diluted 1:1000,
Chemicon) overnight at room temperature followed by
biotinylated secondary antibody (goat anti-rabbit or horse
anti-mouse rat absorbed, or goat anti-rat IgG diluted
1:400, Vector Laboratories, Burlingame, CA, USA) and
NeutrAvidin-HRP (diluted 1:5000, Pierce Biotechnology,
Inc., Rockford, IL, USA). The tissue bound peroxidase
activity was developed with 0.024% diaminobenzadine
(DAB, Sigma), 0.006% H2O2 in 0.05 M Tris–HCl buffer
pH 7.6 for 20 minutes with or without nickel intensification.
Tissue sections were dehydrated in a graded series of
ethanols, immersed in xylene, and coverslipped with
Permount (Fisher Scientific).
Fluorescence immunohistochemistry for Iba1-positive
microglia. Brain sections were stained for microglial
markers using a standard immunofluorescence protocol
[12]. Auto-fluorescence was quenched in 0.2 M glycine
in PBS pH 7.4, for 1 hour at room temperature. Sections
were then permeabilized in 0.3% Triton X-100 with 1%
normal goat serum in 20 mM Tris-buffered saline (TBS)
pH 7.4. Non-specific binding was blocked with species-
appropriate 1% normal serum in TBS. Sections were
incubated overnight at 4°C with an antibody specific
for Iba1 (Wako Chemicals, Richmond, VA, USA, 019–
19741, diluted 1:10000) and followed by Alexa-conjugated
secondary antibody (Fab) (1:1000 dilution, Invitrogen) for
4 hr at room temperature. Antibodies were diluted in
blocking buffer with 0.1% Triton X-100. Washes were
done in TBS with 0.2% Triton X-100 (TBST). Following
secondary antibody incubations, the slides were rinsed
briefly with dH2O, then counterstained with Hoescht
33258 (diluted 1:20,000, Invitrogen) for 15 minutes, and
coverslipped with aqueous mounting media with anti-fade
(Biomeda Corp, Foster City, CA, USA). Quantification
of Iba1-positive cells was performed on images captured
under a 20X objective lens (or 40X for inset images) on
a Nikon 90i fluorescence microscope using thresholding
analysis on Nikon Elements 5 software (Nikon Instru-
ments, Melville, NY, USA). Values represent the mean ±
SEM of Iba1-positive microglia per field from four fields
selected randomly from entorhinal brain sections harvested
from two mice per treatment group.
Stereological analysis
The optical fractionator probe of Stereoinvestigator soft-
ware (MicroBrightField, Inc., Williston, VT, USA) was
used to obtain an unbiased estimate of TH-positive and
NeuN-positive neurons in the SNpc and ventral tegmen-
tal area (VTA) as per the atlas of the mouse brain by
Paxinos and Franklin [38]. Stereologic parameters were
as follows: counting frame, 50 μm × 50 μm; optical dis-
sector: 20 μm; grid size, 120 μm × 160 μm. For the popu-
lation size estimate (number of sections per animal), a
target coefficient of error (Gundersen’s m = 1) of less
than 0.10 was considered acceptable. Neuron counting
was performed by two different investigators blinded to
genotype and treatment history.
Striatal tyrosine hydroxylase fiber density and
densitometry
Coronal serial sections (30 μm thickness) were cut be-
tween Bregma −1.22 to 1.70 on a Leica CM 1850 cryostat
and placed on Superfrost/Plus microscope slides (Fisher
Scientific). Tissue sections were immunostained for TH
and developed using DAB as described above. Images of
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striatum (caudate putamen) from 12 tissue sections per
animal were taken with a CoolSnap cf digital color cam-
era mounted on a BX61 microscope (Olympus, Center
Valley, PA, USA). Exposure times were kept constant
for all images. TH-positive fiber density was determined
using background corrected integrated optical density
measurements for each section using an Alpha Innotech
FluorChem FC2 imaging workstation and software (Pro-
tein Simple, Santa Clara, CA, USA). All sections for each
animal were averaged and group means were used to com-
pare treatment groups.
Striatal dopamine and metabolites
Levels of striatal DA and its metabolites (DOPAC, HVA
and 3-MT) were quantified by HPLC with electrochemical
detection. Mice were euthanized by carbon dioxide
asphyxiation followed by immediate decapitation and
dissection of the striatum on an ice-cold glass Petri dish.
The striatum was then weighed and stored at −80°C. Fro-
zen brain tissue was sonicated in a 49 volume/weight
(mg of tissue) solution of 0.1 M perchloric acid containing
0.2 mM sodium metabisulfite and centrifuged at 20,000 rpm
for 20 minutes at 4°C in a benchtop centrifuge to clear
debris. Cleared supernatant (20 μL) was then injected
onto a C18 HPLC column (ESA MD-150 3 × 150 mm)
and separated by isocratic elution at a flow rate of
0.6 ml/minute using MD-TM mobile phase (ESA Inc.,
Chelmsford, MA, USA). Neurotransmitter monoamines
and metabolites were detected using a BAS electrochem-
ical cell set to a potential of +800 mV and compared to
external standards. Dopamine turnover was calculated
as (DOPAC + HVA + 3-MT)/DA.
Statistics
Multiple-way analysis of variance (ANOVA) with signifi-
cance level α = 0.05 were used as indicated for each set
of experimental data. Significant differences between
groups were further evaluated using Tukey’s HSD or
Bonferroni’s post hoc test. Kruskal-Wallis analysis was
the non-parametric statistical test used for testing equal-
ity of population medians of integrated optical density
measurements of striatal TH fiber density. Graphs were
generated and statistical analyses performed with the
use of GraphPad Prism 5.0 (GraphPad Software, La Jolla,
CA, USA).
Results
Intranasal soluble tumor necrosis factor delivery does not
promote nigral dopamine neuron loss in wild-type or
DJ-1−/− mice
Neuroinflammation can enhance oxidative stress responses
and, based on evidence that DJ-1 plays a protective role
against oxidative stress, we investigated whether DJ-1−/−
mice display increased vulnerability to inflammation-
induced nigral degeneration. First, we tested an inflam-
matory regimen designed to trigger neuroinflammation
directly in the olfactory bulb, a brain region that has
been demonstrated to show early involvement in PD
pathogenesis [39]. We delivered rhodamine-labeled hu-
man TNF (rh-TNF) intranasally to confirm uptake and
transport by nasal epithelia (NE). Immunofluorescence
analyses of cryosectioned rostral and caudal NE tissues
revealed detectable uptake and transport of rh-TNF in
rostral sections of NE at early time points (data not shown).
As expected, the distribution of rh-TNF progressed from
rostral to caudal sections as a function of time (over a
12-hour period). Because TNF can induce cachexia, we
investigated the extent to which inTNF administration
decreased food and water intake. Soluble recombinant
mouse TNF was administered intranasally twice weekly
at one of two doses (0.5 ng or 5 ng) for 1 week or for
2 weeks in wild-type and DJ-1−/− mice. Food consump-
tion and body weight were monitored just prior to and
during the inTNF dosing. Results revealed no adverse
systemic effects (that is, loss of appetite or body weight)
after repeated systemic inTNF dosing (data not shown).
Next, we investigated whether inTNF administration in
wild-type or DJ-1−/− mice resulted in detectable nigral
DA neuron loss. We subjected 12-month old DJ-1−/−
mice and wild-type mice to an inTNF experimental regi-
men that consisted of four initial administrations of
soluble TNF at the lower dose (0.5 ng, chosen to minimize
potentially adverse systemic effects from repeated ad-
ministration) followed by several boost doses (at 0.5 ng)
and a 2-month wait time with the intent to trigger an
inflammatory response that might persist or progress
beyond the initial inflammatory stimulus (Additional
file 1: Figure S1A). Stereological analyses to determine
the extent to which the experimental paradigm induced
nigral DA neuron loss revealed no inTNF-induced nigral
DA neuron loss in mice of either genotype (Additional
file 1: Figure S1B). Consistent with our immunohistological
findings, measurements of striatal DA and DA turnover
by HPLC with electrochemical detection showed no
inTNF-induced neurotransmitter changes in wild-type
or DJ-1−/− mice (Additional file 1: Figure S1C). Com-
pared to other groups, we observed a significant reduc-
tion in striatal DA in vehicle-treated DJ-1−/− mice, but
inTNF administration did not further decrease striatal
DA or affect DA turnover (Additional file 1: Figure S1C).
We considered that the failure of the inTNF regimen
to induce nigral DA neuron degeneration could be
due to a limited neuroinflammatory response. There-
fore, we investigated the extent to which the repeated
inTNF dosing (Additional file 1: Figure S1) triggered
neuroinflammation in wild-type and DJ-1−/− mice. We
found that inTNF exposure did not result in significant
changes in microglia morphology (Figure 1A) or increases
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in microglia number in either wild-type or DJ-1−/− mice
as quantified by Iba1 immunohistochemistry in cortical
sections (Figure 1B). As a positive control for microglial
activation, we included Iba1-positive microglia in wild-
type mice treated with i.p. LPS for 3 months (Figure 1A).
Therefore, because the inTNF regimen failed to trigger a
robust inflammatory response in the midbrain, we opted
to use a different regimen to trigger neuroinflammation in
the midbrain that would allow us to investigate the extent
to which loss of DJ-1 protein might predispose mice to
inflammation-induced nigral degeneration. The regimen
consisted of repeated i.p. LPS injections previously shown
to induce equivalent neuroinflammatory responses in both
wild-type and parkin−/− mice, but significant nigral DA
neuron loss only in parkin−/− mice [33].
DJ-1−/− mice exposed to prolonged, serial low-dose
systemic lipopolysaccharide do not develop locomotor
deficits
To test the hypothesis that DJ-1 regulates vulnerability
to inflammation-related nigral degeneration, we exposed
wild-type and DJ-1−/− mice to various systemic LPS reg-
imens (Figure 2). A number of behavioral tasks were
measured at the time points indicated to investigate the
extent to which the prolonged serial low-dose systemic
LPS regimens induced locomotor alterations. To assess
fine-motor performance, mice were subjected to the
narrow beam-walk test while gross motor abilities were
measured by rotarod and open field performance. Our
results indicate that DJ-1−/− mice chronically injected
with LPS did not display significantly slower average
time-to-cross on the narrow beam-walk test (Figure 3A),
nor did they exhibit reduced performance on the rotarod
(Figure 3B) or altered open field behavior (data not
shown) compared to saline-treated DJ-1−/− mice or wild-
type mice of either treatment group. Thus, in the present
study, prolonged serial i.p. injections of LPS or saline did
not cause gross or fine motor abnormalities.
Chronic low-dose systemic lipopolysaccharide does not
promote loss of nigral dopamine neurons or striatal
dopaminergic terminals in wild-type or DJ-1−/− mice
To estimate the number of DA neurons and total neu-
rons in the SNpc, we performed immunohistochemistry
for TH as the dopaminergic neuronal marker and NeuN
as the pan-neuronal marker. Compared to similarly dosed
wild-type mice, DJ-1−/− mice that received 3 months of
repeated low-dose systemic LPS did not exhibit significant
reductions in TH positive or NeuN positive neurons in
the SNpc (Figure 4A). Similarly, 3 months of repeated
low-dose systemic LPS followed by a 3-month wait period






























WT Saline WT inTNF DJ-1-/- Saline DJ-1-/- inTNF
Iba1
    WT LPS
Figure 1 Intranasal soluble tumor necrosis factor dosing regimen does not induce robust microglia activation in the midbrain.
(A) Immunohistochemical analysis for the microglia marker Iba1 in representative brain sections from cortical regions of wild-type (WT) or DJ-1−/− mice
exposed to repeated intranasal administration of saline or soluble TNF (inTNF) (0.5 ng) as indicated in the experimental paradigm (Additional file 1:
Figure S1A), or to 3-month intraperitoneal lipopolysaccharide (LPS) (See Methods). Scale bar = 200μm. (B) Quantification of Iba1-positive cells within the
entorhinal cortex of inTNF-treated WT or DJ-1−/− mice. Analysis by two-way analysis of variance revealed no gross differences due to genotype or
treatment in microglia morphology or number of Iba1-positive microglia per field (n = 4 fields per treatment group).
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NeuN positive SNpc neurons in DJ-1−/− mice or wild-
type mice (Figure 4A). An ANOVA followed by a Tukey’s
HSD post hoc test indicated a significant (~29%) decrease
in TH-positive nigral neurons in wild-type mice treated
with LPS for 6 months, compared to saline-treated wild-
type mice; however, no significant difference was found
in the number of NeuN-positive nigral neurons (~13%
decrease in LPS-treated compared to saline-treated wild-
type mice), suggesting that these results may reflect
downregulation of TH expression (Figure 4A). The num-
bers of TH- and NeuN-positive neurons were also un-
changed in the VTA (Figure 4B).
In PD, loss of dopaminergic nerve terminals in the
striatum presumably precedes loss of cell bodies within
the SNpc. Therefore, to investigate whether repeated
low-dose systemic LPS affected dopaminergic terminals
in the striatum, we analyzed striatal sections using TH
immunohistochemistry. No decreases in the density of
TH-positive fibers were detectable in striatal brain re-
gions of DJ-1−/− mice treated with low-dose systemic
LPS for 3 or 6 months or for 3 months followed by a
3-month wait period (Figure 5B). Densitometric analysis
of multiple sections indicated that the only significant
change occurred in DJ-1−/− mice exposed to LPS for
3 months; these mice displayed an increase in striatal
TH-positive fiber density (Figure 5A). To extend and
confirm these findings, we measured the tissue levels
of DA and its metabolites in microdissected striatum
by HPLC with electrochemical detection. In agreement
with the immunohistochemical results, repeated low-dose
i.p. LPS injections caused a detectable increase in striatal
DA content in DJ-1−/− mice exposed to the 3-month regi-
men (Figure 5C). The increase in striatal DA in this group
is accompanied by a slight decrease in DA turnover, which
is calculated as the ratio of DA metabolites (DOPAC,
HVA and 3-MT) to DA. There were no significant
wild type &
DJ-1-/- 












3 months of i.p. injections 3 month wait
wild type &




























Figure 2 Schematic of systemic lipopolysaccharide administration regimens and measurable outcomes. Wild-type and DJ-1−/− mice were
given low-dose lipopolysaccharide or an equivalent volume of saline vehicle twice a week intraperitoneally (i.p.) for the indicated times. Locomotor
behavior was evaluated before and during the course of treatment. Groups of mice were sacrificed as indicated for biochemical and immunohistological
analyses. IHC, immunohistochemistry; mo, months; QPCR, quantitative polymerase chain reaction; HPLC, high-performance liquid chromatography.
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differences in levels of DOPAC, HVA or 3-MT levels
(Additional file 2: Figure S2).
Low-dose systemic lipopolysaccharide administration
causes neuroinflammatory responses in midbrains of
DJ-1−/− and wild-type mice
To investigate the possibility that the lack of nigral neuron
loss in LPS-treated DJ-1−/− mice could be attributed to an
attenuated neuroinflammatory response, we used QPCR
to measure the relative mRNA expression of TNF and
CD45 (a marker of activated monocytes also known as
leukocyte common antigen) in the midbrain and cortex
of the mice from the 6-month treatment groups. We
found that basal levels of TNF mRNA were similar in
wild-type and DJ-1−/− mice within the midbrain and
cortex of saline-treated animals, and i.p. LPS treatment
evoked increases in TNF mRNA in the midbrain (but
not cortex) of wild-type and DJ-1−/− mice (Figure 6A,B).
Narrow Beam Walk












































Figure 3 Absence of motor deficits in DJ-1−/− mice exposed to prolonged, serial low-dose systemic lipopolysaccharide. No significant
differences were detected between genotypes or treatment groups in (A) the time to walk across a narrow beam or (B) the time before falling
off an accelerating rotarod, suggesting no general malaise or overt motor deficits compared to wild-type saline-treated mice. Bars represent
mean ± SEM; n = 8 per group. Analysis by three-way analysis of variance followed by a Tukey’s HSD post hoc test at P < 0.05 for significance.
For rotarod: genotype F(1, 232) = 3.46, P = 0.064; treatment F(1, 232) = 0.76, P = 0.383. For beam walk: genotype F(1, 232) = 1.86, P = 0.173;
treatment F(1, 232) = 2,92, P = 0.089. LPS, lipopolysaccharide; mo, months.
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3 months 3 months/3 months 6 months
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Figure 4 DJ-1−/− mice do not display increased vulnerability to nigral dopamine neuron loss induced by repeated low-dose systemic
lipopolysaccharide compared to wild-type mice. Unbiased stereological analysis indicates that DJ-1−/− mice exposed to 3 or 6 months of
low-dose systemic lipopolysaccharide (LPS) or to 3 months of low dose systemic LPS followed by a 3 month wait before analysis do not display a
significant reduction of tyrosine hydroxylase (TH) or NeuN immunopositive neurons in (A) the substantia nigra pars compacta (SNpc) or (B) the ventral
tegmental area (VTA). Error bars represent SEM; analysis includes n = 3 to 7 per group in final cohorts due to attrition. Asterisks indicate significant
differences compared with wild-type, saline-treated mice by three-way analysis of variance followed by Tukey’s HSD post hoc test at P < 0.05.
For SNpc TH neurons: genotype F(1, 47) = 7.89, P = 0.007; treatment F(1, 47) = 0.01, P = 0.904. For SNpc NeuN neurons: genotype F(1, 47) = 1.05,
P = 0.311; treatment F(1, 47) = 0.0.03, P = 0.858. For VTA TH neurons: genotype F(1, 47) = 8.57, P = 0.005, post hoc analysis reveal no significant
differences; treatment F(1, 47) = 0.39, P = 0.536. For VTA NeuN neurons: genotype F(1, 47) = 1.26, P = 0.268; treatment F(1, 47) = 01.28, P = 0.269.
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Figure 5 (See legend on next page.)
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Surprisingly, the level of TNF mRNA was higher in the
midbrains of LPS-treated wild-type mice compared to
LPS-treated DJ-1−/− mice (Figure 6A). Interestingly, the
basal levels of midbrain (but not cortex) CD45 mRNA
were elevated in DJ-1−/− mice relative to wild-type mice,
and i.p. LPS treatment evoked increased CD45 mRNA in
the midbrain of wild-type mice but no further increases
were observed in DJ-1−/− mice over basal levels.
DJ-1−/− mice display blunted anti-oxidant gene
responses relative to wild-type mice after exposure to
repeated low-dose systemic lipopolysaccharide
administration
We next investigated whether the lack of nigral cell loss
in DJ-1−/− mice following repeated, serial systemic low-
dose LPS administration could be attributed to upregulation
of anti-oxidant responses as a developmental consequence
of DJ-1 deficiency. We used QPCR to measure the expres-
sion of key anti-oxidant genes implicated in protection of
DA neurons in the midbrain in wild-type or DJ-1−/− mice
that received a 6-month low-dose systemic LPS admin-
istration or saline control. We analyzed mRNA levels of
the transcription factor NF-E2 related factor (Nrf2),
which binds to the anti-oxidant response element to
induce expression of anti-oxidant and phase 2 detoxifi-
cation enzymes, heme-oxygenase-1 (HO-1), inducible
nitric oxide synthase (iNOS), superoxide dismutase-1
(SOD-1), and superoxide dismutase-2 (SOD-2). We
found upregulation of SOD-1 and SOD-2 mRNA in the
midbrain of saline-treated DJ-1−/− mice compared to
wild-type saline animals (Figure 7). In contrast to wild-
type mice, low-dose peripheral LPS treatment in DJ-1−/−
mice resulted in a significant reduction in SOD-1 and in
SOD-2 mRNA relative to saline treatment. Low-dose
peripheral LPS treatment evoked significant increases in
Nrf2, iNOS, and HO-1 mRNA in the wild-type mice
midbrain but failed to elicit a similar response in DJ-1−/−
mice. Although HO-1 mRNA was significantly increased
in midbrains of LPS-treated DJ-1−/− mice compared to
saline-treated DJ-1−/− mice, it was significantly less than
in LPS-treated wild-type mice. Taken together, LPS treat-
ment did not elicit an upregulation of anti-oxidant genes
in DJ-1−/− mice compared to wild-type mice, indicating a
blunted response in DJ-1−/− midbrains. Therefore,
the lack of inflammation-induced nigral degeneration
was not due to an enhanced anti-oxidant response in
DJ-1−/− mice.
DJ-1−/− and wild-type macrophages display similar
inflammatory and anti-oxidant gene responses
To determine whether the blunted oxidative stress re-
sponse in the midbrain after chronic peripheral inflam-
mation was due to DJ-1 gene ablation in cell types that
typically respond to LPS with inflammatory and oxida-
tive bursts, we isolated peritoneal macrophages from
wild-type or DJ-1−/− mice and tested their responses to
LPS in vitro. QPCR analyses revealed that DJ-1 mRNA
levels are comparable in microglia and peritoneal mac-
rophages (data not shown). Gene expression analyses
of TNF, iNOS, IL-1β, Nrf2, and NQO1 mRNA from
isolated macrophages revealed no difference between
genotypes (Additional file 3: Figure S3). Lastly, our
previous work found that Parkin function may influ-
ence neuroinflammatory responses and vulnerability to
inflammation-induced nigral degeneration [33], and we
considered that perhaps Parkin levels were compensatorily
upregulated in DJ-1−/− mice, and contribute to the lack of
vulnerability of DJ-1−/− mice to inflammation-induced
nigral degeneration. However, we found no differences
between genotypes or treatment groups in the levels of
Parkin mRNA or protein expression in the midbrain
and cortex or in peritoneal macrophages (data not shown).
Discussion
DJ-1 function has been implicated in the regulation
of inflammation-induced oxidative stress in vitro by
reports that LPS can robustly increase DJ-1 expression in
peritoneal macrophages in response to NADPH oxidase-
derived reactive oxygen species [31]. Moreover, DJ-1 has
been shown to be important for mitochondrial function
in astrocytes [40] and DJ-1−/− astrocytes overproduce
nitric oxide when stimulated with LPS [32,41]. On the
basis of these in vitro studies we expected that the
brains of DJ-1−/− mice would display exacerbated
neuroinflammatory responses to chronic inflammatory
stress and would develop a nigral degeneration phenotype,
given that DA neurons are sensitive to neuroinflammation.
However, we found that the neuroinflammatory responses
(See figure on previous page.)
Figure 5 Repeated low-dose intraperitoneal lipopolysaccharide injections do not induce loss of striatal tyrosine hydroxylase-immunopositive
terminals or dopamine depletion in DJ-1−/− or wild-type mice. (A) Densitometric analysis of striatal tyrosine hydroxylase (TH) fiber density indicates
no significant differences between genotypes or treatment groups as indicated by Kruskal-Wallis with Tukey’s post hoc test. Bars represent mean ± SEM;
analysis includes n = 3 to 7 per group in final cohorts due to attrition. The asterisk represents difference between bracketed groups and DJ-1−/− LPS.
(B) Representative striatal sections stained for TH from mice in the 3 month treatment groups; scale bar = 400μm. (C) Striatal levels of dopamine (DA)
were measured by HPLC electrochemical detection for mice in the 3-month treatment group and striatal DA turnover was calculated as the ratio of
DA metabolites (DOPAC, HVA and 3-MT) to DA. Asterisks indicate significant differences compared with wild-type animals by two-way analysis of
variance followed by Bonferroni’s HSD post hoc test at *P < 0.05 and ***P < 0.001 (Genotype effect for DA: F(1,30) = 26.01, P < 0.001; DA turnover:
F(1,29) = 23.49, P < 0.001). IOD, integrated optical density; LPS, lipopolysaccharide; mo, months; DA, dopamine.
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in DJ-1−/− mice after repeated i.p. LPS injection were
similar to that of wild-type mice (Figure 6). Chronic i.p.
LPS exposure induced significant increases in midbrain
TNF levels in both wild-type and DJ-1−/− mice; however,
the TNF levels were higher in LPS-treated wild-type mice
compared to LPS-treated DJ-1−/− mice. It remains pos-
sible that DJ-1−/− mice may have shown significant loss of
nigral dopamine neurons if the LPS dose were increased
to cause midbrain TNF levels to match that of wild-type
mice treated with this dose of LPS. It is worth noting that
the microglia burden measured by Iba-1+ cells in the
brains of DJ-1−/− mice was not different from wild-type
mice (Figure 1), and is consistent with the observation that
the lineage-related myeloid-derived peripheral macrophage
population also displayed inflammatory responses in vitro
that were indistinguishable from wild-type (Additional file 2:
Figure S3). inTNF administration caused no apparent
neuroinflammatory responses in either wild-type or
DJ-1−/− mice. Therefore, the magnitude of the TNF
inflammatory insult may be too low to draw conclusions
regarding the effect of DJ-1 mutations on susceptibility
to TNF neuroinflammation-mediated neurodegeneration.
It remains possible that we would have observed different
responses to TNF in wild-type and DJ-1−/− mice if we
had used a stronger TNF administration regimen.
Functionally, the repeated i.p. LPS injection regimen
which successfully triggered nigral degeneration in parkin
−/− mice [33] did not induce nigral degeneration in DJ-1
−/− mice (Figure 4), suggesting that loss of DJ-1 function
does not increase vulnerability to inflammation-induced
nigral degeneration. Nevertheless, it remains possible that
a higher concentration of inTNF or LPS and/or a longer
regimen (greater than 6 months) and/or longer wait-time































































































































































































































Figure 6 DJ-1−/− display blunted neuroinflammatory responses in midbrain compared to wild-type mice after repeated low-dose
systemic lipopolysaccharide administration. Quantitative PCR analyses of microdissected brain tissue was used to measure expression levels of
the neuroinflammation markers TNF and CD45 in (A) the ventral midbrain and (B) the cortex of mice treated with low-dose systemic
lipopolysaccharide (LPS) (or saline) for 6 months (mo). Parkin mRNA was also measured and found to be similar in both genotypes (data not
shown). *,**Significant difference from wild-type saline; #Significant difference from DJ-1−/− saline; +Significant difference between LPS
conditions. Bars represent mean ± SEM; n = 3 to 4 per group. A two-way analysis of variance was performed with Tukey’s HSD post hoc at P <
0.05 (midbrain TNF treatment effect: F(1,9) = 16.57, P = 0.0028, genotype effect P = 0.29; midbrain CD45 treatment effect: F(1,10) = 9.38, P = 0.0120,
genotype effect P = 0.09; cortex TNF treatment effect: F(1,10) = 6.73, P = 0.0268, genotype effect P = 0.73; cortex CD45: not significant (n.s.),
treatment P = 0.679, genotype P = 0.97).
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i.p. LPS injections and the endpoint of the study may be
required to elicit a more robust neuroinflammatory re-
sponse and uncover increased vulnerability to inflammation-
induced degeneration in DJ-1−/− mice. Although we ob-
served an intriguing increase in striatal TH fiber density
and striatal DA in DJ-1−/− mice treated with LPS for
3 months, we did not observe significant changes in the
cohorts receiving LPS for 6 months or for 3 months with
a 3-month wait period. Some caution should therefore be
exercised in interpreting the unexpected increases in stri-
atal TH fiber density and striatal DA in the 3-month treat-
ment group.
Although DJ-1−/− mice were reported to display nor-
mal numbers of nigral DA neurons in the SNpc, they
were shown to have deficits in dopaminergic function
[17] that are further accentuated when exposed to para-
quat [26] and MPTP [25], suggesting a protective role
for DJ-1 in mitochondrial function and/or against oxida-
tive stress. In support of this molecular model, DJ-1 has
been shown to translocate to mitochondria [20] in re-
sponse to oxidative stress when key cysteine residues be-
come oxidized [18], and to also interact with
multifunctional regulators of transcription and RNA me-
tabolism in the nucleus [42]. In contrast, we found that
mice deficient in DJ-1 displayed blunted oxidative stress
levels in response to LPS treatment relative to wild-type
mice (Figure 7), as measured by expression of Nrf2,
HO-1 and iNOS. However, we found that expression of
SOD-1 and SOD-2 was increased in saline-treated DJ-1
−/− mice compared to saline-treated wild-type mice
(Figure 7), which may reflect compensatory upregulation
of certain anti-oxidants in the absence of DJ-1 and may
have contributed to the attenuated expression of oxida-
tive stress genes in response to LPS. Inflammatory stim-
uli have been reported to exacerbate the oxidative
response of DJ-1−/− cells, and although we did not ob-
serve this in our study, we only reported responses after
chronic LPS treatments (6 months) and did not have the
acute response gene expression after 3 months of LPS
injections to draw conclusions about the kinetics of the
oxidative stress response. Additionally, gene expression
was measured in lysates of whole brain sections and it is
therefore likely that the differences we observed in oxi-
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Figure 7 DJ-1−/− mice display blunted oxidative stress responses to prolonged, serial administration of low-dose systemic
lipopolysaccharide relative to wild-type mice. Real-time quantitative PCR analyses of microdissected midbrain tissue from mice treated with
low-dose lipopolysaccharide (LPS) (or saline) for 6 months (mo) measured expression levels of NF-E2 related factor (Nrf2), heme-oxygenase-1
(HO-1), inducible nitric oxide synthase (iNOS), superoxide dismutase-1 (SOD-1), and superoxide dismutase-2 (SOD-2). *,**Significant difference from
wild-type saline; #Significant difference from DJ-1−/− saline; +Significant difference between the LPS conditions. Bars represent mean ± SEM;
n = 3 to 4 per group. A two-way analysis of variance was performed with Tukey’s HSD post hoc at *P < 0.05 (Nrf2 treatment effect: F(1,10) = 7.96, P = 0.0181,
genotype effect: F(1,10) = 8.28, P = 0.016; HO-1 treatment effect: F(1,10) = 7.56, P = 0.0205, genotype effect: P = 0.166; iNOS not significant:
treatment effect, P = 0.2474, genotype effect, P = 0.183; however, a significant relationship between treatments and genotype did exist (F(1,10) = 5.318,
P = 0.044); SOD-1 treatment effect: F(1,10) = 14.67, P = 0.0033, genotype effect: F(1,10) = 9.47, P = 0.012 SOD-2 treatment effect: not significant, P = 0.5175,
genotype effect: F(1,10) = 7.08, P = 0.024).
Nguyen et al. Journal of Neuroinflammation 2013, 10:50 Page 13 of 15
http://www.jneuroinflammation.com/content/10/1/50
attributed to other cell types in the brain, such as astro-
cytes or neurons which also express SOD-1 and SOD-2,
for example. Interestingly, we also observed that saline-
treated DJ-1−/− mice compared to saline-treated wild-
type mice have increased CD45 in the midbrain. Although
Iba-1 immunostaining indicated no robust changes in
microglia number or activation status, this increased ex-
pression could be due to increased levels of other lympho-
cytes or neutrophils which also express CD45 [43]. Lastly,
given that DJ-1−/− mice have been reported to have
compensatory gene expression in mitochondrial en-
zymes [44], we considered and ruled out the possibility
that compensatory increases in Parkin mRNA and pro-
tein expression accounted for the lack of vulnerability
against inflammation-induced nigral degeneration.
In summary, we conclude that loss of DJ-1 function,
unlike loss of Parkin function, does not confer in-
creased vulnerability to the neurodegenerating effects
of chronic inflammatory insults induced by LPS.
Given the contrasting responses of parkin−/− and DJ-
1−/− mice to repeated i.p. LPS injections, we con-
clude that Parkin and DJ-1 are likely to have distinct
and non-overlapping roles in protecting the nigrostriatal
pathway against inflammatory and neurotoxic insults that
lead to degeneration.
Additional files
Additional file 1: Figure S1. Schematic of intranasal TNF (inTNF)
dosing paradigm in DJ-1−/− and wild type mice and effects on nigral DA
neuron number and striatal DA. A, Schematic of experimental design.
Wild type and DJ-1−/− mice were administered soluble murine TNF
intranasally at the indicated concentrations or an equivalent volume of
saline vehicle for the indicated times. Groups of mice were sacrificed as
indicated for biochemical (striatal DA measurements by HPLC) and
immunohistological (unbiased stereological estimate of nigral DA neuron
number) analyses. B, Unbiased stereological analysis indicates that DJ-1−/−
mice exposed to repeated doses of 0.5 ng TNF intranasally do not
display a significant reduction of TH or NeuN immunopositive neurons
in the SNpc. Error bars represent SEM, n=6-10 per group. Two-way
ANOVA indicated no significant differences (TH: p = 0.085, NeuN: p = 0.257).
C, Striatal dopamine (DA) was measured by HPLC with electrochemical
detection and striatal DA turnover was calculated as the ratio of DA
metabolites (DOPAC, HVA and 3-MT) to DA. Error bars represent SEM,
n = 6–10 per group. Two-way ANOVA, Bonferroni’s post hoc **p < 0.01
compared to wild type saline (DA: F(1,29)= 22.07, p < 0.0001, DA turnover:
not significant, p = 0.055).
Additional file 2: Figure S2. Striatal levels of DA and metabolites for
wild type and DJ-1−/− mice in the 3-month treatment group was
measured by HPLC electrochemical detection. (DOPAC, HVA, and 3-MT
were not significant by two-way ANOVA, p > 0.05 for all).
Additional file 3: Figure S3. Neuroinflammatory and oxidative stress
responses of isolated peritoneal macrophages from DJ-1−/− mice are
similar to wild type. Primary peritoneal macrophages were isolated
from wild type and DJ-1−/− mice and treated with 1 ug/mL LPS for
4 hrs. QPCR was performed for gene expression of TNF, iNOS, IL1b,
NRF2, and NQO1. A two-way ANOVA was performed with Bonferroni’s
post hoc at * for p < 0.05, ** for p < 0.01, and *** for p < 0.001
significance compared to the saline treatment. No genotype differences
were detected (TNF: p = 0.95, iNOS: p = 0.33, IL1β: p = 0.60, NRF2:
p = 0.54, NQO1: p = 0.09).
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